Sunila Pradeep, PhD

Publications

• Optimized proximity ligation assay (PLA) for detection of RNA-protein complex interactions in cell lines.

  (George J, Mittal S, Kadamberi IP, Pradeep S, Chaluvally-Raghavan P.) STAR Protoc. 2022 06 17;3(2):101340 PMID: 35620072 PMCID: PMC9127197 SCOPUS ID: 2-s2.0-85130357879 05/28/2022

• Author Correction: Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation.

  (Zheng Y, Sethi R, Mangala LS, Taylor C, Goldsmith J, Wang M, Masuda K, Carrami EM, Mannion D, Miranda F, Herrero-Gonzalez S, Hellner K, Chen F, Alsaadi A, Albukhari A, Fotso DC, Yau C, Jiang D, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, Knapp S, Gray NS, Campo L, Myers KA, Dhar S, Ferguson D, Bast RC Jr, Sood AK, von Delft F, Ahmed AA.) Nat Commun. 2022 Jun 10;13(1):3352 PMID: 35688808 PMCID: PMC9187678 SCOPUS ID: 2-s2.0-85131828825 06/11/2022

• Tumor Derived Extracellular Vesicles Drive T Cell Exhaustion in Tumor Microenvironment through Sphingosine Mediated Signaling and Impacting Immunotherapy Outcomes in Ovarian Cancer.

  (Gupta P, Kadamberi IP, Mittal S, Tsaih SW, George J, Kumar S, Vijayan DK, Geethadevi A, Parashar D, Topchyan P, McAlarnen L, Volkman BF, Cui W, Zhang KYJ, Di Vizio D, Chaluvally-Raghavan P, Pradeep S.) Adv Sci (Weinh). 2022 05;9(14):e2104452 PMID: 35289120 PMCID: PMC9108620 SCOPUS ID: 2-s2.0-85126251446 03/16/2022

• Correction to: Parashar et al. Patient-Derived Ovarian Cancer Spheroids Rely on PI3K-AKT Signaling Addiction for Cancer Stemness and Chemoresistance (Cancers, (2022), 14, 958)

  (Parashar D, Geethadevi A, Mittal S, McAlarnen LA, George J, Kadamberi IP, Gupta P, Uyar DS, Hopp EE, Drendel H, Bishop EA, Bradley WH, Bone KM, Rader JS, Pradeep S, Chaluvally-Raghavan P.) Cancers. May-2 2022;14(10) SCOPUS ID: 2-s2.0-85129951244 05/01/2022

• Patient-Derived Ovarian Cancer Spheroids Rely on PI3K-AKT Signaling Addiction for Cancer Stemness and Chemoresistance

  (Parashar D, Geethadevi A, Mittal S, McAlarnen LA, George J, Kadamberi IP, Gupta P, Uyar DS, Hopp EE, Drendel H, Bishop EA, Bradley WH, Rader JS, Pradeep S, Chaluvally-Raghavan P.) Cancers. February-2 2022;14(4) SCOPUS ID: 2-s2.0-85124460063 02/01/2022

• Establishment of In Vivo Ovarian Cancer Mouse Models Using Intraperitoneal Tumor Cell Injection.

  (Mittal S, Gupta P, Chaluvally-Raghavan P, Pradeep S.) Methods Mol Biol. 2022;2424:247-254 PMID: 34918299 SCOPUS ID: 2-s2.0-85121752492 12/18/2021

• RNA-binding protein FXR1 drives cMYC translation by recruiting eIF4F complex to the translation start site.

  (George J, Li Y, Kadamberi IP, Parashar D, Tsaih SW, Gupta P, Geethadevi A, Chen C, Ghosh C, Sun Y, Mittal S, Ramchandran R, Rui H, Lopez-Berestein G, Rodriguez-Aguayo C, Leone G, Rader JS, Sood AK, Dey M, Pradeep S, Chaluvally-Raghavan P.) Cell Rep. 2021 11 02;37(5):109934 PMID: 34731628 PMCID: PMC8675433 SCOPUS ID: 2-s2.0-85118477211 11/04/2021

• Oncostatin M Receptor-Targeted Antibodies Suppress STAT3 Signaling and Inhibit Ovarian Cancer Growth.

  (Geethadevi A, Nair A, Parashar D, Ku Z, Xiong W, Deng H, Li Y, George J, McAllister DM, Sun Y, Kadamberi IP, Gupta P, Dwinell MB, Bradley WH, Rader JS, Rui H, Schwabe RF, Zhang N, Pradeep S, An Z, Chaluvally-Raghavan P.) Cancer Res. 2021 10 15;81(20):5336-5352 PMID: 34380633 PMCID: PMC8530981 SCOPUS ID: 2-s2.0-85116424540 08/13/2021

• Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens.

  (Nagaraja AS, Dood RL, Armaiz-Pena G, Kang Y, Wu SY, Allen JK, Jennings NB, Mangala LS, Pradeep S, Lyons Y, Haemmerle M, Gharpure KM, Sadaoui NC, Rodriguez-Aguayo C, Ivan C, Wang Y, Baggerly K, Ram P, Lopez-Berestein G, Liu J, Mok SC, Cohen L, Lutgendorf SK, Cole SW, Sood AK.) JCI Insight. 2021 04 08;6(7) PMID: 33793425 PMCID: PMC8119210 SCOPUS ID: 2-s2.0-85103808072 04/02/2021

• Improving vascular maturation using noncoding RNAs increases antitumor effect of chemotherapy.

  (Mangala LS, Wang H, Jiang D, Wu SY, Somasunderam A, Volk DE, Lokesh GLR, Li X, Pradeep S, Yang X, Haemmerle M, Rodriguez-Aguayo C, Nagaraja AS, Rupaimoole R, Bayraktar E, Bayraktar R, Li L, Tanaka T, Hu W, Ivan C, Gharpure KM, McGuire MH, Thiviyanathan V, Zhang X, Maiti SN, Bulayeva N, Choi HJ, Dorniak PL, Cooper LJ, Rosenblatt KP, Lopez-Berestein G, Gorenstein DG, Sood AK.) JCI Insight. 2021 04 08;6(7) PMID: 33793423 PMCID: PMC8119196 SCOPUS ID: 2-s2.0-85103806720 04/02/2021

• Targeted biologic inhibition of both tumor cell-intrinsic and intercellular CLPTM1L/CRR9-mediated chemotherapeutic drug resistance.

  (Parashar D, Geethadevi A, McAllister D, Ebben J, Peterson FC, Jensen DR, Bishop E, Pradeep S, Volkman BF, Dwinell MB, Chaluvally-Raghavan P, James MA.) NPJ Precis Oncol. 2021 Mar 02;5(1):16 PMID: 33654182 PMCID: PMC7925570 SCOPUS ID: 2-s2.0-85109651282 03/04/2021

• CD63-mediated cloaking of VEGF in small extracellular vesicles contributes to anti-VEGF therapy resistance

  (Ma S, Mangala LS, Hu W, Bayaktar E, Yokoi A, Hu W, Pradeep S, Lee S, Piehowski PD, Villar-Prados A, Wu SY, McGuire MH, Lara OD, Rodriguez-Aguayo C, LaFargue CJ, Jennings NB, Rodland KD, Liu T, Kundra V, Ram PT, Ramakrishnan S, Lopez-Berestein G, Coleman RL, Sood AK.) Cell Reports. 17 August 2021;36(7) SCOPUS ID: 2-s2.0-85112794188 08/17/2021